All In Biotech

Drug Trial Radar · NCT05791318

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants

A Phase 1, Randomized, Triple-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Monoclonal Antibody VYD222 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 28, 2023

Primary completion

May 8, 2024

Study completion May 8, 2024

Sponsor

Lead sponsor
Invivyd, Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Mar 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to investigate the safety, tolerability, and pharmacokinetics of the monoclonal antibody VYD222 in healthy adult participants.

Conditions

  • COVID-19

Interventions

  • VYD222Drug

    Monoclonal antibody

  • PlaceboOther

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAEs (including AEs and SAEs)Time frame: Through 12 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear Clinical Research

    Joondalup, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.